Clinical Trial Update: A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating JNJ-63723283 in combination with daratumumab vs daratumumab alone in relapsed or refractory multiple myeloma has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• JNJ-63723283

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-11-12